Health Care

Eshelman Ventures Invests In RTP Pharmaceutical Developer

By Jenny Callison, posted Apr 16, 2015
Wilmington-based Eshelman Ventures recently made a significant investment in Innocrin Pharmaceuticals Inc., a clinical-stage pharmaceutical company in Research Triangle Park, according to a news release earlier this week.

Eshelman Ventures led Innocrin’s Series D $28 million financing round to support the company’s development of VT-464, a treatment for “resistant hormonally-dependent breast and prostate cancers,” the release stated. Other participants in the Series D round are the company’s existing investors: Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners and A&B Equity Holdings.

Innocrin also announced in the release that Fred Eshelman, founder of Eshelman Ventures, has joined its board of directors.

“I am delighted to be involved with Innocrin,” Eshelman said in the release. “It is a very exciting investment opportunity and the company’s pipeline, particularly VT-464, will hopefully contribute to advances in treating difficult cancers.”

Innocrin officials said the company plans to use the proceeds of this capital raise to accelerate Phase 2 studies of VT-464, which are being led by the Memorial Sloan Kettering Cancer Center in New York City and the National Cancer Institute in Reston, Virginia.

This investment is the fourth Eshelman Ventures has made this year in drug research firms. In February, the venture capital firm announced it had participated in a $3.15 million first-round equity financing for Dignify Therapeutics LLC, to support development of a drug to restore bladder and bowel control to people with spinal cord injuries and spina bifida. Eshelman’s firm also announced in February it was a lead investor in a $33 million Series B financing round for G1 Therapeutics Inc. to underwrite proof-of-concept research for a cancer medication.

The third investment was in Neoantigenics, a Charlottesville, Virginia-based company that specializes in developing oncology “theranostics” – therapeutic and diagnostic – products. Its latest financing round, in which Eshelman Ventures participated, also closed in February.

Eshelman Ventures is interested primarily in making investments in private health care companies, although the firm “will consider other themes that are attractive and have large potential markets,” according to its website. The firm potentially will make angel investments, co-investments with other financial partners in fledgling companies and investments in more established companies.

The firm is its founder's newest business sortie, founded in August 2014, shortly after he sold his drug development firm, Furiex Pharmaceuticals, to Forest Laboratories. Eshelman's highest-profile business to date was Wilmington-based PPD, which the pharmaceutical entrepreneur founded in 1985 as a one-person business. He subsequently relocated the company to Wilmington. PPD was sold in December 2011 to two venture capital firms.
Ico insights


Jeremytomlinson enfuse headshot

3 Unbreakable Rules Of Business Technology

Jeremy Tomlinson - Enfuse Technology Solutions
Drewsmith copiersplus headshot

Should You Upgrade to Windows 11?

Drew Smith - Copiers Plus
Tommytaylor ceo unitedway

GivingTuesday - A Community Wide Celebration of Generosity!

Tommy Taylor - United Way

Trending News

Wrightsville Beach Oceanfront Home Sale Tops May Record

Cece Nunn - Dec 1, 2021

Chamber Releases Economic Scorecard on Wilmington Region 

Johanna F. Still - Dec 1, 2021

Development Proposal Plants Commercial Space On Farm Land

Cece Nunn - Dec 3, 2021

Soup's On At New Asian Restaurant In Porters Neck

Jenny Callison - Dec 1, 2021

With Listening Sessions Complete, New Hanover Endowment Looks Ahead

Johanna F. Still - Dec 2, 2021

In The Current Issue

Chain Reaction: Coping With A Disrupted Supply Chain

The worldwide supply chain disruption is a perfect storm, said Drew Rosen, professor of supply chain management at the University of North C...

Employers Monitor Vaccine Rules

With judicial review underway on the Biden administration’s vaccination mandate for businesses with 100 or more employees, leading employers...

Seniors Find Health, Friends In Fitness

If there’s one word to describe the members of Sandy Sneakers, an exercise group for seniors, it’s “vivacious.” They have the energy of a 30...

Book On Business

The 2021 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!



Trying to Grow a Business?
2020 Health Care Heroes
2020 WilmingtonBiz 100